Tag
NASDAQ: AKBA
Unicycive Therapeutics reports US$59M ahead of March FDA target
Adrian Kessler · Nov 16, 2026
Akebia Therapeutics reports noninferiority in vadadustat dosing trial
Adrian Kessler · Nov 5, 2026
Unicycive Therapeutics resubmits oxylanthanum carbonate NDA to FDA
Adrian Kessler · Sep 29, 2026